The size of the Middle East and Africa Cartilage Regeneration Market was worth USD 71.82 million in 2022. It is further projected to be growing at a CAGR of 8.9% and worth USD 110.00 million by 2027.
The high prevalence and incidence rates of bone and joint disorders and the increasing number of cases of osteoarthritis and orthopedic injuries among the MEA population have resulted in an increased flow of patients to orthopedic clinics and hospitals. These factors are expected to drive the demand for cartilage regeneration in the near future in MEA. According to data released by the World Health Organization, 2016, around 1.5 million people die in traffic accidents worldwide each year due to the influence of drunk driving, reckless cell phone use, and other related factors such as bad weather conditions and inadequate road construction. In addition, there has been an increase in athletic activity in Saudi Arabia, which has raised the incidence of injury in athletes, leading to the demand for cartilage regeneration products. According to Marwan et al., the prevalence of various sports injuries recorded in many Arab nations was between 73% and 90%, especially in teenagers. According to research data from the American Orthopedic Society for Sports Medicine, more than 4 million athletes receive medical treatment for sports injuries each year.
The United Arab Emirates has a significant share of the elderly population. For example, the population over 65 is likely to increase significantly by 2030, according to the Dubai Health Investment Guide data. This increase in the elderly population indicates an increase in chronic diseases, which may increase the demand for cartilage regeneration procedures. In addition, the increasing technological upgrading and advancements in knee cartilage provide opportunities for the MEA cartilage regeneration market.
However, the high cost of cartilage repair surgeries and treatment, the complications associated with cartilage regeneration surgeries in the elderly, and the limited number of cartilage-based stem cell products may slow down the market growth for years to come. Additionally, the lack of skilled professionals and strict government regulations in the region is expected to challenge the market's growth rate during the forecast period.
This research report on the Middle East and Africa cartilage regeneration market has been segmented and sub-segmented into the following categories:
By Type Of Treatment:
Over the studied period, the regional market in Israel is expected to grow with the highest growth rate due to the increase in the number of older people and the availability of technologically advanced medical facilities in the region. Additionally, advancements have been made in the treatment of osteoarthritis, contributing to the growth of the cartilage repair market across the country.
Saudi Arabia is showing significant growth in the Middle East and Africa market due to the increase in road accidents and sports-related injuries. In addition, the government of Saudi Arabia has taken various measures to raise awareness of bone disease and repair. For example, the Department of Health has been vigilant about healthcare awareness to defeat the silent disease. A national osteoporosis awareness campaign was launched on World Osteoporosis Day. The campaign focuses attention on getting tested, treatment, and prevention, especially in women across KSA. In addition, the expansion of cartilage regeneration products will provide significant opportunities for the market in the near future.
The UAE dominates the Middle East and Africa cartilage regeneration market due to the increasing obesity, more cases of injuries and musculoskeletal disorders, increase in healthcare spending, government initiatives focused on providing better health services, and the growing number of health facilities. Notably, the establishment of efficient distribution networks by the country's leading manufacturers is likely to contribute to the future growth of the MEA cartilage regeneration market.
KEY MARKET PLAYERS:
Companies playing a prominent role in the MEA cartilage regeneration market profiled in the report are Zimmer Biomet Holdings, Inc. (U.S.), Vericel Corporation (U.S.), Smith & Nephew plc (U.K.), Osiris Therapeutics, Inc. (U.S.), and Arthrex Inc. (U.S.).
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]